NAVINTA LLC (United States) holds 35 active US FDA Type II Drug Master Files and 4 inactive, has DMF or CEP filings on record for 34 active ingredients, holds 1 active Type IV (excipient) Drug Master File and is linked to 1 FDA-registered manufacturing site. 10 FDA enforcement records are linked to it.

Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records

Cite as: PharmaTek, “NAVINTA LLC: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/navinta-llc

Overview

NAVINTA LLC is an active pharmaceutical ingredient (API) supplier with 36 active FDA Type II Drug Master Files, covering BENDAMUSTINE HYDROCHLORIDE MONOHYDRATE; BENZTROPINE MESYLATE USP; CISATRACURIUM BESYLATE USP; COLESEVELAM HYDROCHLORIDE; CRIZOTINIB; CYCLOPHOSPHAMIDE USP.

Core services & business areas

API ManufacturingPharmaceutical Manufacturing

Active ingredients with DMF or CEP filings

Substances for which NAVINTA LLC holds, or has held, a US FDA Drug Master File or an EU CEP. A filing is not proof of current supply. Open any ingredient to see all its holders, CAS number and product patent dates.

API / Drug Master Files

NAVINTA LLC holds 35 active (39 total) FDA Type II Drug Master Files. A Type II DMF is filed with the FDA to support an active ingredient in drug applications; an active filing can be referenced but is not proof of current supply, and inactive filings are historical.

  • RILPIVIRINE HYDROCHLORIDEActive2026-04-28
  • CISATRACURIUM BESYLATE USPActive2025-06-18
  • GLYCEROL PHENYLBUTYRATEActive2025-04-03
  • SODIUM PHENYLBUTYRATE USPActive2025-02-24
  • TAFAMIDIS MEGLUMINEActive2024-07-29
  • TRIHEPTANOINActive2024-03-26
  • CRIZOTINIBActive2024-01-08
  • DIAZEPAM USPActive2023-09-27
  • COLESEVELAM HYDROCHLORIDEActive2023-07-18
  • CYCLOPHOSPHAMIDE USPActive2023-03-31
  • MARAVIROCActive2022-03-30
  • DS166 DRUG SUBSTANCEActive2022-03-25
  • MIGLUSTATActive2021-11-10
  • PENICILLAMINE USPActive2018-09-28
  • FOSAPREPITANT DIMEGLUMINEActive2018-09-27
  • DS108 DRUG SUBSTANCEActive2018-09-27
  • BENZTROPINE MESYLATE USPActive2018-02-09
  • PHENOXYBENZAMINE HYDROCHLORIDE USPActive2017-12-28
  • SODIUM NITROPRUSSIDE USPActive2017-06-02
  • REMIFENTANIL HYDROCHLORIDEActive2016-09-27
  • ROPIVACAINE HYDROCHLORIDE USPActive2016-09-23
  • PHYTONADIONE USP (PROCESS A)Active2016-09-20
  • TRIENTINE HYDROCHLORIDE USPActive2016-09-15
  • DS121 DRUG SUBTANCEActive2016-09-06
  • MELPHALAN HYDROCHLORIDEActive2015-09-29
  • SEVELAMER HYDROCHLORIDEActive2014-03-25
  • SEVELAMER CARBONATEActive2014-01-02
  • BENDAMUSTINE HYDROCHLORIDE MONOHYDRATEActive2013-09-19
  • TAUROLIDINEActive2010-12-28
  • HYDRALAZINE HYDROCHLORIDE USP (P) GRADEActive2010-10-28
  • HYDRALAZINE HYDROCHLORIDE USPActive2006-10-26
  • NICARDIPINE HYDROCHLORIDE USPActive2006-09-15
  • FOMEPIZOLEActive2006-08-10
  • ROPIVACAINEActive2005-12-30
  • SODIUM FERRIC GLUCONATE COMPLEXActive2005-07-29
  • CYCLOPHOSPHAMIDE USP (STERILE)Inactive2021-09-28
  • SODIUM 4-PHENYLBUTYRATEInactive2007-07-18
  • DEFEROXAMINE MESYLATE USPInactive2007-02-09
  • IRON SUCROSE COMPLEXInactive2005-04-11

Excipient Drug Master Files

NAVINTA LLC holds 1 active (1 total) FDA Type IV Drug Master File. A Type IV DMF covers an excipient, colourant or flavour, not an active ingredient; these are counted separately from the API filings above.

Registered manufacturing sites (1)

Physical sites registered with the US FDA and resolved to NAVINTA LLC, with any EU/UK GMP documents matched to each site. Headquarters and manufacturing locations can differ.

FDA compliance signals

10 FDA enforcement records linked to this company.

  • 4832019-03-28

    Failure to submit scientific article

  • 4832017-08-18

    Failure to maintain records

  • 4832017-08-18

    Incomplete periodic safety report

  • 4832017-08-18

    Late submission of 15-day report

  • 4832017-08-18

    Late submission of an ICSR

  • warning_letter2016-09-26

    FDA Warning Letter (drug product)

  • 4832016-05-16

    Timely submission

  • 4832016-05-16

    Interval

  • 4832016-05-16

    Failure to develop written procedures

  • recall — Class II2015-04-15

    Lack of Assurance of Sterility. A recent FDA inspection reported GMP violations potentially impacting product quality and sterility.

For suppliers

Is this NAVINTA LLC?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.

Need suppliers found and checked?

The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.